Cargando…

Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?

Glioblastoma (GBM) is the most malignant primary brain tumor without effective therapies. Since bevacizumab was FDA approved for targeting vascular endothelial growth factor receptor 2 (VEGFR2) in adult patients with recurrent GBM, targeted therapy against receptor tyrosine kinases (RTKs) has become...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Anna, Musket, Anna, Musich, Phillip R, Schweitzer, John B, Xie, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598918/ https://www.ncbi.nlm.nih.gov/pubmed/34806012 http://dx.doi.org/10.1093/noajnl/vdab133

Ejemplares similares

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
por: Montor, Wagner Ricardo, et al.
Publicado: (2018)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
por: Tilak, Manali, et al.
Publicado: (2021)

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018)

Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
por: Carrasco-García, Estefanía, et al.
Publicado: (2014)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches
por: Alexandru, Oana, et al.
Publicado: (2020)

Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma
por: Scherschinski, Lea, et al.
Publicado: (2022)

miR-219-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in Glioblastoma
por: Rao, Soumya Alige Mahabala, et al.
Publicado: (2013)

Druggability analysis and classification of protein tyrosine phosphatase active sites
por: Ghattas, Mohammad A, et al.
Publicado: (2016)

Druggable Transient Pockets in Protein Kinases
por: Umezawa, Koji, et al.
Publicado: (2021)

Co-survival of the fittest few: mosaic amplification of receptor tyrosine kinases in glioblastoma
por: Chen, Feng, et al.
Publicado: (2012)

Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases
por: Xu, Yin, et al.
Publicado: (2016)

Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
por: Land, Craig A., et al.
Publicado: (2020)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sudhesh Dev, Sareshma, et al.
Publicado: (2021)

Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites
por: Merritt, Christopher, et al.
Publicado: (2014)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma
por: Jones, DeAnalisa C., et al.
Publicado: (2018)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma
por: Burford, Anna, et al.
Publicado: (2013)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Rnd3 Is a Crucial Mediator of the Invasive Phenotype of Glioblastoma Cells Downstream of Receptor Tyrosine Kinase Signalling
por: Almarán, Beatriz, et al.
Publicado: (2022)

A druggable copper-signalling pathway that drives inflammation
por: Solier, Stéphanie, et al.
Publicado: (2023)

Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates
por: Kastenhuber, Edward R., et al.
Publicado: (2013)

Flotillins in Receptor Tyrosine Kinase Signaling and Cancer
por: Banning, Antje, et al.
Publicado: (2014)

Ligand bias in receptor tyrosine kinase signaling
por: Karl, Kelly, et al.
Publicado: (2021)

The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
por: Torrisi, Filippo, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Aldaz, Paula, et al.
Publicado: (2021)

DRUGGABLE MM THERAPEUTICS: PATHOGENETIC PATHWAYS
por: Ocio, Enrique M
Publicado: (2022)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2020)

Tyrosine Kinase Receptors in Oncology
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2020)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
por: Wu, Xinyan, et al.
Publicado: (2021)

Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis
por: Azad, Taha, et al.
Publicado: (2020)

Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells
por: Affinito, Alessandra, et al.
Publicado: (2020)

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets
por: Kanojia, Deepika, et al.
Publicado: (2017)

Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
por: Liu, Feng, et al.
Publicado: (2016)

Gamma-secretase-dependent signaling of receptor tyrosine kinases
por: Merilahti, Johannes A.M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lgidosolucnj60ej7qapn5ilu7